More importantly, besides the drug inhibition on tumor cell functions, we observed more significant inhibition on expressions of the drug targets, and activity of associated signaling molecules in EGFRvIII-expressing but not vector GBM cells, i.e. integrin αν, β3, p-EGFRvIII, p-FAK, p-SRC, MMP2, MMP9, etc. (Figure 7E and Supplementary Figure S2F). The gene discussed is PTK2; the disease is neoplasm.